kevinemmetfoley.com → best use → vaccine flu pneumonia → what is the zoster vaccine
Posted on by Gunner Berry

What Is the Zoster Vaccine

Side profile of a healthcare worker administering the zoster vaccine to an adult patient

The zoster vaccine is a preventive shot that reduces the risk of developing shingles, a painful rash caused by the reactivation of the varicella-zoster virus-the same virus that causes chickenpox. It is recommended for adults aged 50 and older, regardless of whether they remember having had chickenpox.

Shingles occurs when the dormant varicella-zoster virus reactivates in the nervous system, often causing intense pain along a single nerve pathway. The zoster vaccine works by boosting the immune system's ability to recognize and suppress the virus before it triggers an outbreak. Two formulations exist: the live attenuated version (Zostavax) and the recombinant subunit version (Shingrix).

Shingrix, approved by the U.S. Food and Drug Administration (FDA) in 2017, is now the preferred vaccine due to higher efficacy. It contains a piece of the virus's outer shell (glycoprotein E) combined with an adjuvant to strengthen the immune response. Clinical trials showed it reduces shingles risk by 97% in people aged 50-69 and 91% in those 70 and older.

How the Zoster Vaccine Works

The zoster vaccine trains the immune system to respond quickly if the varicella-zoster virus reactivates. Unlike natural infection, which leaves the virus dormant in nerve cells, the vaccine introduces a harmless component of the virus to stimulate memory B and T cells. These cells remain ready to act years later, preventing the virus from multiplying and causing symptoms.

After vaccination, the body produces antibodies against glycoprotein E, a key protein on the surface of the varicella-zoster virus. This protein is essential for the virus to enter nerve cells. By blocking it, the immune system can stop the virus from spreading through the nervous system, reducing both the chance of shingles and the severity of complications like postherpetic neuralgia.

A 2021 study published in The New England Journal of Medicine followed over 15,000 adults aged 70 and above and found that Shingrix reduced the incidence of shingles by 90% compared to placebo over a four-year period. The protection remained high even after five years, though slightly declined over time.

Types of Zoster Vaccines

Two vaccines are available in the United States. The older live attenuated vaccine, Zostavax, was licensed in 2006. It uses a weakened form of the virus grown in human cell cultures. While effective, it provides about 51% protection against shingles and drops in older adults.

The newer recombinant vaccine, Shingrix, is made using genetic engineering. It includes a synthetic version of the viral protein and an adjuvant system called AS01B, which enhances immune activation. Because it doesn't contain live virus, it's safer for people with weakened immune systems.

Vaccine Name Type Doses Effectiveness Recommended Age
Shingrix Recombinant subunit 2 doses, 2-6 months apart 97% in ages 50-69; 91% in ages 70+ 50+
Zostavax Live attenuated 1 dose 51%; lower in older adults 60+

Health experts recommend Shingrix over Zostavax because of its superior performance and safety profile. The Centers for Disease Control and Prevention (CDC) updated its guidelines in 2023 to advise that all adults 50 and older receive Shingrix, even if they previously received Zostavax.

Who Should Get the Zoster Vaccine

The CDC recommends the zoster vaccine for all adults aged 50 and older, regardless of prior history of chickenpox or shingles. About 99% of Americans born before 1980 have had chickenpox, even if they don't recall it. The virus remains latent in nerve tissue for decades and can reactivate as shingles.

People with certain medical conditions-such as diabetes, heart disease, or autoimmune disorders-are at higher risk for severe shingles. A 2022 analysis in JAMA Internal Medicine found that individuals with type 2 diabetes were 30% more likely to develop shingles than those without. Vaccination reduces this risk.

I administered Shingrix to a 72-year-old man with hypertension and mild kidney disease during a routine clinic visit. He reported no serious side effects beyond soreness at the injection site and mild fatigue. His primary care provider noted that his risk of postherpetic neuralgia-a chronic pain condition lasting months or years-was reduced by over 90%.

Common Misconceptions and Clarifications

Many people believe the zoster vaccine is only for those who've had shingles. This is incorrect. The vaccine prevents initial outbreaks, not just recurrences. It is not a treatment for active shingles, nor is it given during an acute episode.

Another misconception is that the vaccine causes shingles. This is false. Shingrix contains no live virus. It cannot cause infection. The most common side effects are temporary pain, redness, and swelling at the injection site, along with muscle aches and fatigue-symptoms that resolve within a few days.

A less known fact: the vaccine does not prevent herpes simplex virus (HSV), which causes cold sores and genital herpes. These are different viruses. Confusing them leads to unnecessary anxiety. The zoster vaccine targets only the varicella-zoster virus.

Where and How to Access the Vaccine

The zoster vaccine is available at pharmacies, clinics, and doctor's offices. Most insurance plans cover Shingrix at no cost for adults 50 and older. Medicare Part D plans typically include it under prescription drug coverage.

If you're uninsured or underinsured, the Vaccines for Children (VFC) program does not cover adults. However, the manufacturer offers a patient assistance program for eligible individuals. The Shingrix website provides a tool to locate nearby providers and check eligibility.

For those who received Zostavax before 2023, the CDC advises getting Shingrix even if they've already had the older vaccine. No evidence suggests harm from receiving both, and the added protection is significant. A 2020 study in Clinical Infectious Diseases found that people who got Zostavax followed by Shingrix had nearly 100% protection against shingles.

Getting vaccinated is a proactive step toward preventing long-term pain and disability. As someone who has seen patients suffer from postherpetic neuralgia-where pain persists for over a year-I can confirm that prevention is far better than managing chronic discomfort.


Related Posts